Pilot Biomarker Study of the Integrin AlphavBeta3 Antagonist Cilengitide (EMD121974) in Combination With Sunitinib.
Phase of Trial: Phase II
Latest Information Update: 21 Jul 2015
At a glance
- Drugs Cilengitide (Primary) ; Sunitinib
- Indications Glioblastoma; Solid tumours
- Focus Biomarker; Pharmacodynamics
- 10 Jun 2017 Biomarkers information updated
- 26 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 14 May 2010 New trial record